Lipocine (LPCN) Stock Price, News & Analysis

Company Overview

Lipocine Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for conditions with significant unmet medical needs. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of poorly bioavailable compounds, with the goal of offering alternatives to injectable or otherwise inconvenient treatments.

Lipocine’s development programs have included oral hormone-replacement therapies, treatments for central nervous system disorders, and therapies for metabolic and liver-related conditions. Its lead product, TLANDO (testosterone undecanoate), was approved by the U.S. Food and Drug Administration in 2022 as an oral testosterone-replacement therapy for adult males with conditions associated with a deficiency or absence of endogenous testosterone.

Based in Salt Lake City, Utah, Lipocine has historically focused primarily on the U.S. pharmaceutical market while advancing its pipeline through clinical development and commercial partnerships. The company is led by Mahesh Karande, who has served as its president and chief executive officer. Lipocine continues to evaluate and develop additional candidates based on its oral drug-delivery platform.

Key Stats

• Today's Range: $1.58 to $1.68
• 50-Day Range: $1.62 to $2.45
• 52-Week Range: $1.58 to $12.37
• Volume: 89,920 shs
• Average Volume: 736,365 shs
• Market Capitalization: $13.03 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Hold

Lipocine Stock Analysis - MarketRank™

Lipocine scored higher than 86% of companies evaluated by MarketBeat, and ranked 54th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

Lipocine has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Lipocine has a consensus price target of $4.00, representing about 150.8% upside from its current price of $1.60.

Amount of Analyst Coverage

Lipocine has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lipocine are expected to grow in the coming year, from ($1.54) to ($1.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lipocine is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lipocine is -0.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lipocine has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.24% of the float of Lipocine has been sold short.

Short Interest Ratio / Days to Cover

Lipocine has a short interest ratio ("days to cover") of 2.26, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Lipocine has recently decreased by 1.64%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lipocine does not currently pay a dividend.

Dividend Growth

Lipocine does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: N/A

News Sentiment

Lipocine has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Lipocine this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

3 people have added Lipocine to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.1 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $82,174.00 in company stock, which represents 0.6249% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $82,174.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

4.69% of the stock of Lipocine is held by insiders.

Percentage Held by Institutions

9.11% of the stock of Lipocine is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/16/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LPCN
• CIK: 1535955
• Web: www.lipocine.com
• Phone: (801) 994-7383
• Fax: 801-994-7388
• Employees: 14
• Year Founded: 1997

Price Target and Rating

• Average Price Target for Lipocine: $4.00
• High Price Target: $4.00
• Low Price Target: $4.00
• Potential Upside/Downside: +150.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.63 million
• Net Margins: -755.39%
• Pretax Margin: -755.26%
• Return on Equity: -64.75%
• Return on Assets: -57.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.48
• Quick Ratio: 11.48

Sales & Book Value

• Annual Sales: $1.57 million
• Price / Sales: 8.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.61 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 8,244,000
• Free Float: 7,857,000
• Market Cap: $13.15 million
• Optionable: No Data
• Beta: 0.40